Oncolytics Biotech Targets Immuno-Oncology Growth with Innovative Treatments and Promising Trial Results

### Oncolytics Biotech Positions Itself in the Growing Immuno-Oncology Sector

Oncolytics Biotech Inc. is making significant strides in the rapidly evolving oncology market, which is projected to experience substantial growth from $279.98 billion in 2026 to an estimated $748.17 billion by 2035. This transformation underscores a pivotal shift from conventional single-agent cancer treatments to more effective combination therapies and state-of-the-art cell therapies. Within this burgeoning industry, the immuno-oncology sector stands out, expected to surge from $65.22 billion in 2025 to $170.19 billion by 2032. The driving force behind this growth is a multitude of newly approved combination therapies that specifically target tumors that have historically resisted treatment, positioning Oncolytics Biotech to thrive in a dynamic environment.

At the forefront of Oncolytics Biotech's innovation is its lead drug, pelareorep, which is set to be highlighted at the upcoming American Association for Cancer Research (AACR) Annual Meeting. Recent studies, including the AWARE-1 trial for breast cancer and the GOBLET trial focusing on gastrointestinal malignancies, demonstrate pelareorep’s potential to increase sensitivity to existing immunotherapies. These trials offer promising data: in the GOBLET trial, patients with pancreatic cancer receiving pelareorep showed a progression-free survival rate of 7.5 months, significantly outpacing the 5.6 months recorded for those not benefiting from early immune activation. Furthermore, for first-line pancreatic cancer patients treated with pelareorep, the objective response rate achieved stands at an impressive 62%, which greatly surpasses the results typically associated with conventional chemotherapy.

As the landscape of biopharma evolves, Oncolytics Biotech finds itself in a favorable position as experts predict record deal-making within the industry leading up to 2026. Notably, financial analysts, including those from Goldman Sachs, underscore that the confluence of accelerated FDA approvals for innovative therapies and a keen interest in combination strategies forms an optimal environment for companies like Oncolytics that aim to capitalize on these shifts. The anticipated advancements in pelareorep and its applications are expected to reflect broader trends in oncological treatment, ultimately improving patient outcomes and reshaping therapeutic paradigms in cancer care.

In the context of these developments, Oncolytics Biotech remains committed to pioneering efforts in oncology, focusing on enhancing the effectiveness of existing treatments and expanding the frontiers of immuno-oncology. With critical presentations and research data on the cusp of release, the company stands poised to further solidify its position as a key player in the future landscape of cancer therapeutics.